The short version of lyophilized powder fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-08 and is reviewed periodically as new material appears.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
CD98 is a glycoprotein that is a heterodimer composed of SLC3A2 and SLC7A5 that forms the large neutral amino acid transporter (LAT1). LAT1 is a heterodimeric membrane transport protein that preferentially transports branched-chain (valine, leucine, isoleucine) and aromatic (tryptophan, tyrosine, phenylalanine) amino acids. LAT is highly expressed in brain capillaries (which form the blood–brain barrier) relative to other tissues. A functional LAT1 transporter is composed of two proteins encoded by two distinct genes:
== Prout's Hypothesis == Prout's hypothesis was an early 19th-century attempt to explain the properties of the chemical elements using the internal structure of the atom. In 1815, the English chemist William Prout observed that the atomic weights that had been measured were integer multiples of the atomic weight of hydrogen. Prout's hypothesis remained influential in chemistry throughout the 1820s. However, more careful measurements of the atomic weights, such as those compiled by Jöns Jakob Berzelius in 1828 or Edward Turner in 1832, appeared to disprove it. In particular the atomic weight of chlorine, which is 35.45 times that of hydrogen, could not at the time be explained in terms of Prout's hypothesis. It would take the better part of a century for this problem to be resolved.
Dy2O3 + 6 HClO4 → 2 Dy(ClO4)3 + 3 H2O Solutions used in modern spectroscopic work have been prepared directly from Dy2O3 and concentrated perchloric acid. Dysprosium perchlorate hexahydrate has also been obtained by dissolving Dy2O3 in 50–60% perchloric acid, followed by removal of excess water under reduced pressure or by freeze-drying. Anhydrous Dy(ClO4)3 can be obtained by controlled dehydration of hydrated dysprosium perchlorate.
==== Omnipod 5 ==== The Omnipod 5, manufactured by Insulet, is a tubeless insulin pump system that can be integrated with the Dexcom G6 and G7 systems to provide automated glucose control. The system was released in the US in June 2024. Users can control the system through the Omnipod 5 Controller or a compatible Android smartphone. Omnipod 5 App for iPhone is expected to be released in the first half of 2025. The system allows for a simplified pairing process through a QR code scan and features a shortened 30-minute CGM warm-up period, compared to the Dexcom G6, enabling more time spent in Automated Mode. The system uses real-time glucose data to adjust insulin delivery.
Tertiary structure — domains The tertiary structure is formed by two domains known as the large and the small, which are separated by a cleft centred around the location of the bond with ATP-ADP+Pi. Below this there is a deeper notch called a "groove". In the native state, despite their names, both have a comparable depth. The normal convention in topological studies means that a protein is shown with the biggest domain on the left-hand side and the smallest domain on the right-hand side. In this position the smaller domain is in turn divided into two: subdomain I (lower position, residues 1–32, 70–144, and 338–374) and subdomain II (upper position, residues 33–69). The larger domain is also divided in two: subdomain III (lower, residues 145–180 and 270–337) and subdomain IV (higher, residues 181–269). The exposed areas of subdomains I and III are referred to as the "barbed" ends, while the exposed areas of domains II and IV are termed the "pointed" ends. This nomenclature refers to the fact that, due to the small mass of subdomain II actin is polar; the importance of this will be discussed below in the discussion on assembly dynamics. Some authors call the subdomains Ia, Ib, IIa, and IIb, respectively.
Sources: en.wikipedia.org
=== Direct mechanism === Two types of drugs are mainly prescribed to people suffering from overwhelming sexual desire: gonadotropin-releasing hormone agonists (GnRH agonists) and steroidal anti-androgens.
DSV Shinkai 6500 discovered vesicomyid clam communities in the Southern Mariana Forearc. They depend on methane, which originates in serpentinite. Other chemosynthetic communities would depend on hydrocarbon origins organic substance in crust, but these communities depend on methane originating from inorganic substances from the mantle. In 2011, the area around the Japan Trench suffered from the Tōhoku earthquake. There are cracks, methane seepages, and bacterial mats which were probably created by the earthquake.
During World War II, wartime manufacturing expanded urban employment for black job seekers who were historically underrepresented in Detroit's labor market as labor policies sanctioned hiring discrimination. Despite the expansion of employment available to black Detroiters, racial integration within the workplace was met with fierce opposition from Blue-collar white employees. For these white Detroiters, black employment harbored intense housing competition within Detroit's overcrowded neighborhoods in addition to crumbling the economic stability of Detroit's white middle class. Therefore, as racial integration within the workplace alluded to racially fluid neighborhoods, the white middle class engaged in residential segregation by using discriminatory behavior and policy to regulate black residential agency and accessibility to homeownership. Transitioning into the postwar period, the economic hardships of manufacturing industries, stemming from suburbanization, along with overpriced rental housing, forced urban black communities to fall on hard times, devolving into decrepit remnants of Detroit's industrial surgency and booming wartime economy. The mass migration of hopeful blacks from the Jim Crow-perpetuated racism and segregation of the South into Northern neighborhoods coupled with sluggish housing construction flooded Detroit with overpopulation, limited funding, and residential mistreatment. Black families faced large down payments, high-interest land contracts, and high maintenance costs of living facilities.
==== Specimen storage and stability ==== Blood specimens for complete blood count (CBC) analysis should ideally be analysed as soon as possible after collection to minimise pre-analytical changes. When delays are unavoidable, EDTA-anticoagulated blood may be stored under refrigerated conditions (2–8 °C), although the stability of individual CBC parameters varies. Haemoglobin concentration and red blood cell and white blood cell counts are generally more stable during refrigerated storage than platelet-related parameters and some red blood cell indices. Laboratories should follow validated storage recommendations and consider potential analytical changes when interpreting delayed specimens. Blood tests are also used to identify autoimmune diseases and Immunoglobulin E-mediated food allergies (see also Radioallergosorbent test).
==== Step 2: Coupling ==== A 0.02–0.2 M solution of nucleoside phosphoramidite (or a mixture of several phosphoramidites) in acetonitrile is activated by a 0.2–0.7 M solution of an acidic azole catalyst, 1H-tetrazole, 5-ethylthio-1H-tetrazole, 2-benzylthiotetrazole, 4,5-dicyanoimidazole, or a number of similar compounds. More extensive information on the use of various coupling agents in oligonucleotide synthesis can be found in a recent review. The mixing is usually very brief and occurs in fluid lines of oligonucleotide synthesizers (see below) while the components are being delivered to the reactors containing solid support. The activated phosphoramidite in 1.5 – 20-fold excess over the support-bound material is then brought in contact with the starting solid support (first coupling) or a support-bound oligonucleotide precursor (following couplings) whose 5'-hydroxy group reacts with the activated phosphoramidite moiety of the incoming nucleoside phosphoramidite to form a phosphite triester linkage. The coupling of 2'-deoxynucleoside phosphoramidites is very rapid and requires, on small scale, about 20 s for its completion. In contrast, sterically hindered 2'-O-protected ribonucleoside phosphoramidites require 5-15 min to be coupled in high yields. The reaction is also highly sensitive to the presence of water, particularly when dilute solutions of phosphoramidites are used, and is commonly carried out in anhydrous acetonitrile. Generally, the larger the scale of the synthesis, the lower the excess and the higher the concentration of the phosphoramidites is used.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.